6-Methyl-1-thia-6-azaspiro[3.3]heptane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫杂环丁烷
• 英文名称: 6-Methyl-1-thia-6-azaspiro[3.3]heptane
• 英文别名: 6-methyl-1-thia-6-azaspiro[3.3]heptane
• 化学式: C₆H₁₁NS
• 分子量: 129.23
• InChiKey: SOSUACOQNGSOGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  28.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160129011A1

  公开（公告）日：2016-05-12

  BET-protein-inhibitory, in particular BRD4-inhibitory bicyclo- and spirocyclically substituted 2,3-benzodiazepines of the general formula (I), pharmaceutical compositions comprising the compounds according to the invention, and the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders, are described. Furthermore, the use of BET protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control is described.

  BET蛋白抑制剂，特别是BRD4抑制剂，具有一般式(I)的双环和螺环替代的2,3-苯二氮䓬类化合物，以及包含该发明化合物的药物组合物，以及其用于治疗过度增殖性疾病，特别是肿瘤性疾病的预防和治疗方法被描述。此外，描述了BET蛋白抑制剂在良性增生、动脉粥样硬化疾病、败血症、自身免疫疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化疾病和男性生育控制中的用途。
• BET PROTEIN-INHIBITING 5-ARYL TRIAZOLE AZEPINES
  申请人：Künzer Helga

  公开号：US20150299201A1

  公开（公告）日：2015-10-22

  The present invention relates to BET-protein-inhibitory, in particular BRD4-inhibitory 5-aryltriazoloazepines of the general formula (I) in which R 1 , R 2 , R 3 and R 4 have the meanings given for the general formula (I), to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for neoplastic disorders. The present invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.

  本发明涉及BET蛋白抑制剂，特别是通式（I）中R1、R2、R3和R4所给定的含有5-芳基三唑并[5,4]氮杂癸烷的化合物，以及包含本发明化合物的制药组合物，以及预防和治疗增生性疾病，特别是恶性肿瘤的用途。本发明还涉及在病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化性疾病和男性生育控制中使用BET蛋白抑制剂。
• [EN] N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES<br/>[FR] N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOÉTHYL)-QUINOLÉINE-4-CARBOXAMIDES
  申请人：ASTRAZENECA AB

  公开号：WO2022130270A1

  公开（公告）日：2022-06-23

  Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5and R6are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

  具有公式（I）结构及其药学上可接受的盐的化合物，其中X1，R1，R2，R3，R4，R5和R6如规范中所定义; 包括此类化合物和盐的制药组合物; 使用此类化合物和盐来治疗或预防脯氨酰内切酶成纤维细胞激活蛋白（FAP）介导的疾病; 包含此类化合物和盐的试剂盒; 以及制造此类化合物和盐的方法。
• BET-PROTEININHIBITORISCHE 5-ARYL-TRIAZOLO-AZEPINE
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2900672B1

  公开（公告）日：2017-02-22
• US9663523B2
  申请人：——

  公开号：US9663523B2

  公开（公告）日：2017-05-30